M. Milanese

Baroreceptor sensitivity and baroreceptor effectiveness index in cirrhosis: the relevance of hepatic venous pressure gradient

Background: Autonomic dysfunction has been reported as one of the complications of cirrhosis.

525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS

Pinzello8, Alessia M. Giorgini9, Massimo Zuin9, Andrea Salmi10, Paolo Del Poggio11, Francesca De Filippi12, Savino Bruno12, Luisa Pasulo13, Stefano Fagiuoli13, Marco Andreoletti14, Agostino Colli14, Francesco Fumagalli Maldini15, Maria Milanese15, Alberto Eraldo Colombo16, Giorgio Bellati16, Elena Angeli17, Carlo Magni17, Guido A. Gubertini17, Giuliano Rizzardini17, Massimo Fasano18, Teresa Santantonio19, Natalia M. Terreni20, Giancarlo Spinzi20, Floriana Facchetti1, Federica Invernizzi1, Massimo Colombo1 Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months

522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY

Angela Testa7, Pasquale Narciso7, Giorgio Antonucci7, Maria Vinci8, Giovambattista Pinzello8, Erika Fatta9, Silvia Fargion9, Paolo Del Poggio10, Barbara Coco11, Maurizia R. Brunetto11, Marco Andreoletti12, Agostino Colli12, Massimo Fasano14, Teresa Santantonio13, Guido Colloredo15, Luisa Pasulo16, Stefano Fagiuoli16, Alberto Eraldo Colombo17, Giorgio Bellati17, Francesco Fumagalli Maldini18, Maria Milanese18, Massimo Pozzi19, Natalia M. Terreni20, Giancarlo Spinzi20, Michela Quagliuolo21, Mauro Borzio21, Giovanna Lunghi22, Massimo Colombo1 Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUCnaive patients with chronic hepatitis B : a 4-year field practice, multicenter study

Heart Function and Myocardial Tissue Characterization in Patients with HCV Related Cirrhosis: Diastolic Dysfunction and Cardiac Hypertrophy

Evidence of diastolic dysfunction in cirrhosis contributed to the definition of cirrhotic cardiomyopathy. In 109 patients with chronic HCV infection with or without cirrhosis E/A ratio, a Doppler marker of diastolic dysfunction, was decreased in cirrhotics (0.89 ± 0.03 vs controls 1.21 ± 0.07, p < 0.01) and to a lesser extent in patients with advanced liver fibrosis (1.17 ± 0.07, p < 0.01). Left ventricular parietal wall thickness was increased. The nature of this abnormality in human cirrhosis has not been clarified, animal studies reporting cardiac hypertrophy. To this aim we employed the echo- cardiographic integrated backscatter (IBS) technique to obtain an indirect estimate of tissue density (decreased when a higher percentage of muscle fibres is present and increased when fibrosis prevails) to provide myocardial tissue charac- terization in a subset of patients with compensated HCV cirrhosis. The average IBS signal was reduced in cirrhotics at the level of the posterior wall (21.72 ± 1.46 dB versus 30.85 ± 1.40 dB in controls, p < 0.01). Our results confirm diastolic dysfunction in postviral cirrhosis pointing to cardiac hypertrophy as the anatomopathological background in the compen- sated stage of disease.

T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment

direct anti-hepatitis B agents; however, prevalence and clinical impact of this adverse event are poorly appreciated. Material and Methods: 124 patients (78% males, 58 yr, 60% cirrhosis, 14% with 2(OH)-vitamin D deficiency, 90% under tenofovir±lamivudine treatment for 15 months) underwent two dual energy X-ray absorptiometry (DXA) of the lumbar spine (LS) and femoral neck (FN) performed at least 12 months a part. A T score of less than -2.5 and a T score between -1 and -2.5 identified osteoporosis and osteopenia, respectively (WHO criteria). All patients lacked concomitant medication affecting bone metabolism or osteoporosi in the first DXA scan. Results: During a median interval of 15 months (12-50) between DXA scan, 13 (26%) of 50 (40%) patients with normal BMD at the first DXA scan progressed to osteopenia (3 at LS, 7 at FN and 3 at both LS and FN) but none to osteoporosis. Among the 74 (60%) patients with osteopenia at the first DXA scan, 5 (7%) progressed to osteoporosis (2 at LS, 2 at FN and 1 at both LS and FN). Overall, 77% of the patients had stable BMD, 8% improved and 15% worsened. Median LS and FN T scores remained stable between DXA scans (-0.70 vs -0.80; -1.10 vs -1.10, p=ns). Age, gender, BMI, cirrhosis, nucleotide treatment, duration of antiviral therapy, immunosuppression and vitamin D status were not associated with worsening of BMD. In conclusion, in patients with chronic hepatitis B under nucleos(t)ide therapy, BMD worsened in a minority of patients only.

OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS

ENTECAVIR FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS P. Lampertico ∗ ,1, M. Vigano1, F. Facchetti 1 , F. Suter 2, E. Minola2, O. Fracassetti 2 , G. Carosi 3, M. Puoti 3, G. Rizzardini 4 , G. Gubertini 4 , C. Magni4, G. Antonucci 5 , A. Testa5, P. Del Poggio6, S. Fargion7, E. Fatta7, M. Brunetto 8 , B. Coco8, A. Colli 9 , M. Andreoletti 9 , T. Santantonio10 , M. Fasano11, G. Colloredo12 , L. Pasulo13, M. Milanese14 , N. Terreni 15, M. Borzio16, R. Soffredini 1 , G. Lunghi17, M. Colombo1 11st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Policlinico, Mangiagalli, Regina Elena, University of Milan, Milan; 2Infectious Diseases, Ospedali Riuniti di Bergamo, Bergamo; 3Department of Infectious Diseases, University of Brescia, AO Spedali Civili, Brescia; 4I and II Division Infectious Diseases, Luigi Sacco Hospital, Milan; 5INMI, L. Spallanzani IRCCS, Rome; 6Ospedale di Treviglio, Treviglio; 7Internal Medicine 1b, Fondazione IRCCS Maggiore Hospital Policlinico, University of Milan, Milan; 8UO Epatologia, Azienda Ospedaliero-Universitaria Pisana, Pisa; 9S.C. Medicina Generale, Ospedale “A. Manzoni”, Lecco; 10Clinic of Infectious Diseases, University of Foggia, Foggia; 11Clinic of Infectious Diseases, University of Bari, Bari; 12Division of Medicine, Policlinico San Pietro, Bergamo; 13Gastroenterology Unit, Liver and Lung Transplantation Centre, Ospedali Riuniti di Bergamo, Bergamo; 14Liver Center, Clinica Medica, Azienda Ospedaliera S. Gerardo, Universita Milano Bicocca, Monza; 15UO Gastroenterologia, Ospedale Valduce, Como; 16UO Gastroenterologia, Azienda Ospedaliera di Melegnano, Melegnano; 17Institute of Preventive Medicine, Fondazione IRCCS Maggiore Hospital, University of Milan, Milan